CHMP recommends Xalkori (Pfizer) for treatment of NSCLC - 22-Jul-2012

On 19 July 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Xalkori (crizotinib), 200 mg, 250 mg, hard capsule from Pfizer and intended for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced Non-Small Cell Lung Cancer (NSCLC) . The benefits with Xalkori are its important activity on ALK-positive NSCLC with an objective response rate of 60% (95% CI, 51% - 69%) and a median progression free survival (PFS) of 9.2 months (95% CI, 7.3 months – 12.7 months).

Related News

Phase III study of Tomtovok (Boehringer) meets endpoint for NSCLC

IDMC halts Phase III study of Vargatef (Boehringer) in NSCLC

FDA approves Tarceva (Genentech/Astellas) for NSCLC as detected by cobas EGFR Mutation Test

NICE rejects Xalkori (Pfizer) for treatment of Non Small Cell Lung Cancer

CRLX 101 (Cerulean Pharma) fails in Phase II trial for NSCLC

NICE rejects extended use of Alimta (Eli Lilly) in NSCLC

Phase III trial of Stimuvax (Merck Serono) fails to meet primary endpoint in patients with NSCLC

New Phase II trial shows combination treatment with selumetinib (AstraZeneca) has promise for patients with NSCLC

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Results positive for Afinitor (Novartis) in BOLERO-3 study in HER2 positive Breast Cancer

19 May 2013

Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced Breast Cancer showed that Afinitor (everolimus) tablets,...

Read full article

Study of Prolia (Amgen/GSK) plus teriparatide shows significant benefits in Osteoporosis

19 May 2013

A randomised, controlled trial of postmenopausal women with Osteoporosis shows that teriparatide and Prolia (denosumab), from Amgen/GSK,...

Read full article